Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, RVMD, ARGX, TVTX, MDGL, and represent 24.21% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: UNH (+$14M), XBI (+$8.6M), IMNM (+$7.5M), RAPT (+$7.2M), CNTA (+$6.4M), NBIX (+$5.1M), SGRY, PTCT, TERN, RCUS.
- Started 18 new stock positions in LEGN, CORT, UNH, ROIV, RCUS, PTCT, JAZZ, ERAS, OLMA, TEVA. TNGX, SGRY, Indivior, IMNM, TBPH, TERN, CYTK, RAPT.
- Reduced shares in these 10 stocks: MRUS (-$56M), ARGX (-$33M), AKRO (-$30M), GPCR (-$14M), INSM (-$11M), CDTX (-$9.8M), MREO (-$9.4M), COGT (-$5.7M), AGIO, CMPX.
- Sold out of its positions in AKRO, Applied Therapeutics, CRL, IMVT, CATX, KRRO, MREO, NVAX, WST, PRTA. CGEN, MRUS.
- Rock Springs Capital Management was a net seller of stock by $-84M.
- Rock Springs Capital Management has $2.0B in assets under management (AUM), dropping by 13.95%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 98 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 5.8 | $113M | 105k | 1074.68 |
|
|
| Revolution Medicines (RVMD) | 5.5 | $106M | 1.3M | 79.65 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 4.5 | $87M | -27% | 103k | 840.95 |
|
| Travere Therapeutics (TVTX) | 4.3 | $85M | +2% | 2.2M | 38.21 |
|
| Madrigal Pharmaceuticals (MDGL) | 4.2 | $81M | 140k | 582.34 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 3.8 | $74M | -3% | 695k | 107.04 |
|
| EXACT Sciences Corporation (EXAS) | 3.1 | $61M | 602k | 101.56 |
|
|
| Mirum Pharmaceuticals (MIRM) | 3.1 | $60M | 762k | 78.99 |
|
|
| Insmed Com Par $.01 (INSM) | 2.8 | $56M | -17% | 319k | 174.04 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.7 | $52M | -21% | 748k | 69.55 |
|
| Intuitive Surgical Com New (ISRG) | 2.4 | $46M | 82k | 566.36 |
|
|
| Cidara Therapeutics Com New (CDTX) | 2.3 | $45M | -17% | 205k | 220.89 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.2 | $43M | -5% | 204k | 213.24 |
|
| Irhythm Technologies (IRTC) | 2.1 | $42M | 235k | 177.44 |
|
|
| Kymera Therapeutics (KYMR) | 2.0 | $39M | +10% | 497k | 77.81 |
|
| Boston Scientific Corporation (BSX) | 2.0 | $38M | +10% | 399k | 95.35 |
|
| Penumbra (PEN) | 1.9 | $38M | 121k | 310.91 |
|
|
| Xenon Pharmaceuticals (XENE) | 1.8 | $35M | -7% | 788k | 44.82 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.7 | $32M | -7% | 734k | 44.05 |
|
| Cogent Biosciences (COGT) | 1.5 | $30M | -15% | 849k | 35.52 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.5 | $29M | 1.3M | 23.00 |
|
|
| Vera Therapeutics Cl A (VERA) | 1.5 | $29M | -7% | 569k | 50.64 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.5 | $28M | -4% | 71k | 397.65 |
|
| Amicus Therapeutics (FOLD) | 1.4 | $28M | 1.9M | 14.24 |
|
|
| Spdr Series Trust State Street Spd (XBI) | 1.4 | $27M | +46% | 222k | 121.93 |
|
| Tenet Healthcare Corp Com New (THC) | 1.3 | $25M | 125k | 198.72 |
|
|
| Dex (DXCM) | 1.2 | $23M | +9% | 347k | 66.37 |
|
| Agios Pharmaceuticals (AGIO) | 1.1 | $22M | -16% | 799k | 27.22 |
|
| Tarsus Pharmaceuticals (TARS) | 1.1 | $21M | -9% | 260k | 81.88 |
|
| Compass Therapeutics (CMPX) | 1.1 | $21M | -12% | 3.9M | 5.37 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.1 | $21M | -6% | 589k | 35.08 |
|
| Brooks Automation (AZTA) | 1.0 | $19M | +5% | 569k | 33.26 |
|
| Celldex Therapeutics Com New (CLDX) | 1.0 | $19M | -4% | 693k | 27.16 |
|
| Caris Life Sciences (CAI) | 1.0 | $19M | -13% | 688k | 26.98 |
|
| Zenas Biopharma (ZBIO) | 0.9 | $18M | -13% | 502k | 36.31 |
|
| Dyne Therapeutics (DYN) | 0.9 | $18M | +10% | 913k | 19.56 |
|
| Neurocrine Biosciences (NBIX) | 0.9 | $18M | +39% | 126k | 141.83 |
|
| Pharvaris N V (PHVS) | 0.9 | $17M | 623k | 27.75 |
|
|
| Mineralys Therapeutics (MLYS) | 0.8 | $16M | +4% | 428k | 36.29 |
|
| Phreesia (PHR) | 0.8 | $15M | +17% | 877k | 16.92 |
|
| Zai Lab Adr (ZLAB) | 0.7 | $14M | +2% | 812k | 17.64 |
|
| Danaher Corporation (DHR) | 0.7 | $14M | 62k | 228.92 |
|
|
| UnitedHealth (UNH) | 0.7 | $14M | NEW | 41k | 330.11 |
|
| Ardelyx (ARDX) | 0.7 | $13M | 2.3M | 5.83 |
|
|
| Aclaris Therapeutics (ACRS) | 0.7 | $13M | -3% | 4.5M | 3.01 |
|
| Summit Therapeutics (SMMT) | 0.6 | $12M | 710k | 17.49 |
|
|
| Enliven Therapeutics (ELVN) | 0.6 | $12M | +16% | 798k | 15.40 |
|
| Inspire Med Sys (INSP) | 0.6 | $12M | +18% | 131k | 92.23 |
|
| Omada Health (OMDA) | 0.6 | $12M | -19% | 740k | 15.78 |
|
| Soleno Therapeutics (SLNO) | 0.6 | $11M | +59% | 247k | 46.30 |
|
| Arcellx Common Stock (ACLX) | 0.6 | $11M | -5% | 170k | 65.20 |
|
| Evolent Health Cl A (EVH) | 0.5 | $11M | -9% | 2.7M | 4.00 |
|
| Gossamer Bio (GOSS) | 0.5 | $10M | 3.3M | 3.10 |
|
|
| Mbx Biosciences (MBX) | 0.5 | $8.9M | 283k | 31.54 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.4 | $8.1M | +367% | 324k | 25.01 |
|
| Heartflow Inc/Sh (HTFL) | 0.4 | $8.1M | +11% | 278k | 29.15 |
|
| Bridgebio Pharma (BBIO) | 0.4 | $7.9M | +21% | 104k | 76.49 |
|
| Regeneron Pharmaceuticals (REGN) | 0.4 | $7.8M | -10% | 10k | 771.87 |
|
| Immunome (IMNM) | 0.4 | $7.5M | NEW | 348k | 21.48 |
|
| Rapt Therapeutics Com New (RAPT) | 0.4 | $7.2M | NEW | 214k | 33.87 |
|
| Bicara Therapeutics (BCAX) | 0.4 | $7.2M | +15% | 429k | 16.83 |
|
| Edwards Lifesciences (EW) | 0.4 | $7.0M | -6% | 83k | 85.25 |
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.3 | $6.6M | 9.6M | 0.69 |
|
|
| Alphatec Hldgs Com New (ATEC) | 0.3 | $6.4M | 303k | 21.04 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.3 | $6.0M | 500k | 12.08 |
|
|
| Thermo Fisher Scientific (TMO) | 0.3 | $5.8M | 10k | 579.45 |
|
|
| Janux Therapeutics (JANX) | 0.3 | $5.0M | +70% | 359k | 13.80 |
|
| Surgery Partners (SGRY) | 0.2 | $4.8M | NEW | 310k | 15.45 |
|
| Eyepoint Com New (EYPT) | 0.2 | $4.7M | +717% | 259k | 18.27 |
|
| Ptc Therapeutics I (PTCT) | 0.2 | $4.7M | NEW | 62k | 75.96 |
|
| Agilon Health (AGL) | 0.2 | $4.5M | -6% | 6.5M | 0.69 |
|
| Mersana Therapeutics (MRSN) | 0.2 | $4.4M | 153k | 28.93 |
|
|
| Terns Pharmaceuticals (TERN) | 0.2 | $4.4M | NEW | 109k | 40.40 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.2 | $4.3M | NEW | 180k | 23.83 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.2 | $4.2M | 1.3M | 3.29 |
|
|
| Ocular Therapeutix (OCUL) | 0.2 | $4.2M | +15% | 346k | 12.14 |
|
| Lenz Therapeutics (LENZ) | 0.2 | $4.1M | +8% | 258k | 16.00 |
|
| Talphera Com New (TLPH) | 0.2 | $4.1M | 3.6M | 1.14 |
|
|
| Sionna Therapeutics (SION) | 0.2 | $4.1M | 99k | 41.14 |
|
|
| Theravance Biopharma (TBPH) | 0.2 | $3.9M | NEW | 209k | 18.71 |
|
| Alkermes SHS (ALKS) | 0.2 | $3.9M | +30% | 139k | 27.98 |
|
| Apellis Pharmaceuticals (APLS) | 0.2 | $3.8M | +63% | 151k | 25.12 |
|
| Indivior Ord | 0.2 | $3.8M | NEW | 105k | 35.88 |
|
| Erasca (ERAS) | 0.2 | $3.5M | NEW | 952k | 3.72 |
|
| Tango Therapeutics (TNGX) | 0.2 | $3.4M | NEW | 387k | 8.86 |
|
| Olema Pharmaceuticals (OLMA) | 0.1 | $2.5M | NEW | 98k | 25.00 |
|
| Cytokinetics Com New (CYTK) | 0.1 | $2.3M | NEW | 36k | 63.54 |
|
| Vaxcyte (PCVX) | 0.1 | $2.2M | +323% | 47k | 46.14 |
|
| Neurogene (NGNE) | 0.1 | $2.1M | 104k | 20.60 |
|
|
| Jasper Therapeutics Com New (JSPR) | 0.1 | $2.0M | 1.1M | 1.83 |
|
|
| Roivant Sciences SHS (ROIV) | 0.1 | $1.9M | NEW | 89k | 21.70 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.1 | $1.7M | NEW | 50k | 34.80 |
|
| Acadia Healthcare (ACHC) | 0.1 | $1.7M | -29% | 120k | 14.19 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.1 | $1.4M | NEW | 46k | 31.21 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.0 | $813k | +118% | 62k | 13.18 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.0 | $735k | NEW | 34k | 21.74 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.0 | $298k | NEW | 1.8k | 170.00 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $44k | 134k | 0.33 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2025 Q4 filed Feb. 17, 2026
- Rock Springs Capital Management 2025 Q3 filed Nov. 14, 2025
- Rock Springs Capital Management 2025 Q2 filed Aug. 14, 2025
- Rock Springs Capital Management 2025 Q1 filed May 15, 2025
- Rock Springs Capital Management 2024 Q4 filed Feb. 14, 2025
- Rock Springs Capital Management 2024 Q3 filed Nov. 14, 2024
- Rock Springs Capital Management 2024 Q2 filed Aug. 14, 2024
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022